The United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Aurangabad manufacturing facility. The inspection was carried out from May 6 to May 15, 2019.
The inspection at the Aurangabad facility closed with three observations. The company is confident of addressing them satisfactorily.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.